<DOC>
	<DOCNO>NCT01581684</DOCNO>
	<brief_summary>The primary objective current study investigate safety , tolerability pharmacokinetics BI 411034 healthy male volunteer follow oral administration single rise dos . The secondary objective explore dose proportionality BI 411034 CYP2C19 ( Cytochrome P450 ) genotyped extensive metabolisers ( EM ) . Another objective compare safety pharmacokinetic profile two different group CYP2C19 genotyped subject , extensive metabolisers ( EM ) poor metabolisers ( PM )</brief_summary>
	<brief_title>Safety Tolerability Pharmacokinetic BI 411034</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male subject Exclusion criterion : 1 . Any relevant deviation healthy condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>